Market Cap 36.59M
Revenue (ttm) 0.00
Net Income (ttm) 2.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 15,100
Avg Vol 206,832
Day's Range N/A - N/A
Shares Out 2.15M
Stochastic %K 20%
Beta -0.23
Analysts Strong Sell
Price Target $34.38

Company Profile

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer'...

Industry: Biotechnology
Sector: Healthcare
Phone: 416 847 6898
Fax: 416 847 6899
Address:
1920 Yonge Street, Suite 200, Toronto, Canada
Blueknoser
Blueknoser Mar. 21 at 1:48 AM
$PMN Food for thought when calculating market cap: EpiSelect™ is a proprietary, patented target discovery platform developed by ProMIS Neurosciences. This technology is designed to identify "Disease Specific Epitopes" (DSEs)—unique molecular surfaces on toxic oligomers (misfolded proteins) that drive neurodegenerative diseases such as Alzheimer's, ALS, and Parkinson's. Key Aspects of ProMIS Neurosciences' EpiSelect™ Patent: Purpose: To generate misfolding-specific antibodies and vaccines that target toxic proteins without interfering with normal protein function. Clinical Application: The platform is used to develop therapeutics like PMN310, which specifically targets toxic amyloid-beta oligomers without affecting normal amyloid-beta monomers or fibrils. Targeted Diseases: Alzheimer's disease (AD), multiple system atrophy (MSA), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Parkinson’s disease. ProMIS Neurosciences, Inc.
0 · Reply
sangysmith
sangysmith Mar. 20 at 1:41 PM
$PMN We have presentation from 1400 to 1800 hours today.
0 · Reply
sangysmith
sangysmith Mar. 20 at 4:39 AM
$PMN ProMIS is expanding beyond Alzheimer’s → now targeting: ALS Parkinson’s This signals a shift toward becoming a multi-disease platform biotech, not a single-asset story Proprietary platform identifies disease-specific epitopes on toxic proteins Works like a “sniper” → targets only harmful misfolded proteins Avoids healthy proteins → potentially safer & more effective 1. ALS Vaccine (Pre clinical) Targets misfolded TDP-43 protein Goal: Stop spread of toxic protein Protect motor neurons Important: TDP-43 is involved in most ALS cases 2. Parkinson’s Vaccine (Pre Clinical) Targets toxic alpha-synuclein oligomers Competes with big pharma programs Key advantage: More selective targeting vs competitors → better safety potential Current TAM ALS - 4 to 5 Billion Parkinson - 7 to 8 Billion ALZ - 8 to 10 billion Total TAM for PMN - 20 billion. 200 million market cap right now wont be surprising which is $95 per share.
0 · Reply
sangysmith
sangysmith Mar. 19 at 8:16 PM
$PMN 2 more !!! https://www.promisneurosciences.com/news-media/press-releases/detail/264/briefglance-com-promis-unveils-precision-vaccines-for-als
0 · Reply
Cellsci
Cellsci Mar. 19 at 4:36 PM
$PMN there’s you 2$ swing
0 · Reply
Tubular9988
Tubular9988 Mar. 19 at 2:46 PM
$PMN there is no dilution from selling stockholders. its only relating to recent private placement. price will interesting and could give pmn a significant boost.
0 · Reply
tonkotsu
tonkotsu Mar. 18 at 8:53 PM
$PMN This may drop further. It doesn’t matter to me as I believe in the science. This stock’s movement is exactly why I don’t average up. Only average down. And quite frankly, I want it to drop further so I can buy more below my cost basis of around 10.
1 · Reply
MoxeysPal
MoxeysPal Mar. 18 at 7:39 PM
$PMN sold half my holdings @20, we're being scammed.
1 · Reply
MoxeysPal
MoxeysPal Mar. 18 at 7:36 PM
$PMN continues to delute , I won't be surprised if it's $5 soon... Wellington Biomedical Innovation Master Investors (Cayman) II L.P. may be deemed to beneficially own an aggregate of 895,877 shares (the "Shares") of Common Stock, of ProMIS Neurosciences Inc. (the "Issuer"). The 895,877 Shares reported as beneficially owned on this Schedule 13G consists of (i) 696,378 Shares held directly by Wellington Biomedical Innovation Master Investors (Cayman) II L.P., (ii) 199,499 Shares underlying warrants (the "Warrants") held directly by Wellington Biomedical Innovation Master Investors (Cayman) II L.P. The securities beneficially owned by each Filer excludes 496,879 Shares underlying Warrants which contain an issuance limitation that prohibits the holder from exercising the Warrants to the extent that after giving effect to such issuance after the exercise, the holder (together with the holder's affiliates and any other persons acting as a group together with the holder or any of the holders
0 · Reply
sangysmith
sangysmith Mar. 18 at 2:06 PM
$PMN Good news 2 more pipelines getting ready. Excited.
0 · Reply
Latest News on PMN
ProMIS Neurosciences Announces Reverse Stock Split

Nov 24, 2025, 8:00 AM EST - 4 months ago

ProMIS Neurosciences Announces Reverse Stock Split


ProMIS Neurosciences Announces Private Placement Financing

Jul 28, 2025, 7:00 AM EDT - 8 months ago

ProMIS Neurosciences Announces Private Placement Financing


ProMIS Neurosciences Issues Letter to Shareholders

Jan 13, 2025, 10:30 AM EST - 1 year ago

ProMIS Neurosciences Issues Letter to Shareholders


ProMIS Neurosciences, Inc. Announces Leadership Transition

Jan 3, 2024, 7:00 AM EST - 2 years ago

ProMIS Neurosciences, Inc. Announces Leadership Transition


Blueknoser
Blueknoser Mar. 21 at 1:48 AM
$PMN Food for thought when calculating market cap: EpiSelect™ is a proprietary, patented target discovery platform developed by ProMIS Neurosciences. This technology is designed to identify "Disease Specific Epitopes" (DSEs)—unique molecular surfaces on toxic oligomers (misfolded proteins) that drive neurodegenerative diseases such as Alzheimer's, ALS, and Parkinson's. Key Aspects of ProMIS Neurosciences' EpiSelect™ Patent: Purpose: To generate misfolding-specific antibodies and vaccines that target toxic proteins without interfering with normal protein function. Clinical Application: The platform is used to develop therapeutics like PMN310, which specifically targets toxic amyloid-beta oligomers without affecting normal amyloid-beta monomers or fibrils. Targeted Diseases: Alzheimer's disease (AD), multiple system atrophy (MSA), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Parkinson’s disease. ProMIS Neurosciences, Inc.
0 · Reply
sangysmith
sangysmith Mar. 20 at 1:41 PM
$PMN We have presentation from 1400 to 1800 hours today.
0 · Reply
sangysmith
sangysmith Mar. 20 at 4:39 AM
$PMN ProMIS is expanding beyond Alzheimer’s → now targeting: ALS Parkinson’s This signals a shift toward becoming a multi-disease platform biotech, not a single-asset story Proprietary platform identifies disease-specific epitopes on toxic proteins Works like a “sniper” → targets only harmful misfolded proteins Avoids healthy proteins → potentially safer & more effective 1. ALS Vaccine (Pre clinical) Targets misfolded TDP-43 protein Goal: Stop spread of toxic protein Protect motor neurons Important: TDP-43 is involved in most ALS cases 2. Parkinson’s Vaccine (Pre Clinical) Targets toxic alpha-synuclein oligomers Competes with big pharma programs Key advantage: More selective targeting vs competitors → better safety potential Current TAM ALS - 4 to 5 Billion Parkinson - 7 to 8 Billion ALZ - 8 to 10 billion Total TAM for PMN - 20 billion. 200 million market cap right now wont be surprising which is $95 per share.
0 · Reply
sangysmith
sangysmith Mar. 19 at 8:16 PM
$PMN 2 more !!! https://www.promisneurosciences.com/news-media/press-releases/detail/264/briefglance-com-promis-unveils-precision-vaccines-for-als
0 · Reply
Cellsci
Cellsci Mar. 19 at 4:36 PM
$PMN there’s you 2$ swing
0 · Reply
Tubular9988
Tubular9988 Mar. 19 at 2:46 PM
$PMN there is no dilution from selling stockholders. its only relating to recent private placement. price will interesting and could give pmn a significant boost.
0 · Reply
tonkotsu
tonkotsu Mar. 18 at 8:53 PM
$PMN This may drop further. It doesn’t matter to me as I believe in the science. This stock’s movement is exactly why I don’t average up. Only average down. And quite frankly, I want it to drop further so I can buy more below my cost basis of around 10.
1 · Reply
MoxeysPal
MoxeysPal Mar. 18 at 7:39 PM
$PMN sold half my holdings @20, we're being scammed.
1 · Reply
MoxeysPal
MoxeysPal Mar. 18 at 7:36 PM
$PMN continues to delute , I won't be surprised if it's $5 soon... Wellington Biomedical Innovation Master Investors (Cayman) II L.P. may be deemed to beneficially own an aggregate of 895,877 shares (the "Shares") of Common Stock, of ProMIS Neurosciences Inc. (the "Issuer"). The 895,877 Shares reported as beneficially owned on this Schedule 13G consists of (i) 696,378 Shares held directly by Wellington Biomedical Innovation Master Investors (Cayman) II L.P., (ii) 199,499 Shares underlying warrants (the "Warrants") held directly by Wellington Biomedical Innovation Master Investors (Cayman) II L.P. The securities beneficially owned by each Filer excludes 496,879 Shares underlying Warrants which contain an issuance limitation that prohibits the holder from exercising the Warrants to the extent that after giving effect to such issuance after the exercise, the holder (together with the holder's affiliates and any other persons acting as a group together with the holder or any of the holders
0 · Reply
sangysmith
sangysmith Mar. 18 at 2:06 PM
$PMN Good news 2 more pipelines getting ready. Excited.
0 · Reply
DARKP00L
DARKP00L Mar. 18 at 12:07 PM
$PMN 08:04 on Mar. 18 2026 ProMIS Neurosciences To Highlight Data On ALS & Parkinsons Disease Programs At AD/PD 2026 International Conference #tradeideas
0 · Reply
Tubular9988
Tubular9988 Mar. 17 at 7:56 PM
$PMN roaring comeback today and yesterday. uptrend on PMN continues.
3 · Reply
Kgra
Kgra Mar. 17 at 2:14 PM
$PMN the 175m offering clearly noted it was participated by the ceo , mgt and bod . Anyone know how much they participated with ? In filings ? This is crazy that many insiders participated in that offering , They know something clearly , and were happy with price
1 · Reply
Blueknoser
Blueknoser Mar. 17 at 1:35 PM
$PMN how high's the water Mama? That song comes to mind where this is going.... with the co-founder buying it at $24+ and he considers that a buy! The sky's the limit and this is going to burst within a few months!!!
0 · Reply
Blueknoser
Blueknoser Mar. 17 at 1:22 PM
$PMN https://www.promisneurosciences.com/investors/news-events/press-releases/detail/258/promis-neurosciences-announces-new-peer-reviewed "The analysis, conducted by Pentara Corporation in collaboration with scientists from ProMIS, provides important new evidence that plasma phosphorylated tau (pTau181 and pTau217) can serve as a meaningful primary endpoint in early-stage AD clinical trials, with potential to predict subsequent clinical benefit." - The analysis, conducted by Pentara Corporation in collaboration with scientists from ProMIS, provides important new evidence that plasma phosphorylated tau (pTau181 and pTau217) can serve as a meaningful primary endpoint in early-stage AD clinical trials, with potential to predict subsequent clinical benefit. - this is going to help Promis go from a clinical 1b study to Phase 3. - Insiders are heavily investing because they know it's a giant success. - a therapeutic for AD with no side effects or ARIA will be the holy grail and make Biogen's Adunucanab and Elly Lilly's Dononamab redundant! - Market Cap? Billions. JMHO
1 · Reply
biospeculator
biospeculator Mar. 17 at 12:46 PM
$PMN Great news. Based on further due diligence and the new number of shares based on the PIPE financing and the warrants resulting in massive dilution from approx. 2M shares up to 14M shares plus based on my gorilla math I am no longer following this stock. Also based in Toronto is a red flag for me as Toronto and Boca Raton Florida are hotbeds for pump and dumps. GLTA and Goodbye.
0 · Reply
7DAYSDIMENSIONS
7DAYSDIMENSIONS Mar. 17 at 12:46 AM
$PMN weak hands couldn't hold... the strong hands showed up today. One guy bought 10,000 shares at 18.05. That's significant. Let's see if it's an insider.
1 · Reply
Kgra
Kgra Mar. 16 at 10:34 PM
$PMN insiders putting personal funds in typically only means they know more than we do also not sure how the new fda position on approving after a single trial will impact us here ? FDA was not clear on such in regards to trials underway , expecting good pr end q2.
0 · Reply
Tubular9988
Tubular9988 Mar. 16 at 7:11 PM
$PMN @biospeculator the chances of PMN falling back to $6 anytime soon are nil and PMN would only do so if their phase 1b is a dud. none of the signs show it is going to be and the upside is potentially massive. some of us have been posting since PMN was $6, not some ’Jonny Come Lately’ who arrives at $20 and wishes the stock was $6.
4 · Reply
MoxeysPal
MoxeysPal Mar. 16 at 3:07 PM
$PMN the last time this was up was on March 5th I think there's something fishy about this.
0 · Reply
biospeculator
biospeculator Mar. 16 at 1:04 PM
$PMN I almost exclusively trade biotech. I never short. Having said that, my target is currently $4-$6 for this stock. Recent capital raise is long term bullish but as noted targets have been reduced to reflect the increased float. Technicals are bearish with a bearish MACD cross and with lower highs followed by lower lows. The company is very early stage at 1b trial with cash burn ahead it's only asset. Then why am I here? The technicals are long term a bullish falling wedge pattern my favorite. There have been several "pumps" of significance in the past once the stock falls back into the wedge which in this case is $4-$6 when I would be a buyer for the next "pump". GLTA I am currently long SLS, TENX, RADX.
6 · Reply
Cellsci
Cellsci Mar. 13 at 6:24 PM
$PMN close @18.80+ ?
0 · Reply